pubmed.ncbi.nlm.nih.gov

Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease - PubMed

  • ️Fri Jan 01 2016

Review

Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease

John K MacDonald et al. Cochrane Database Syst Rev. 2016.

Abstract

Background: Ustekinumab (CNTO 1275) and briakinumab (ABT-874) are monoclonal antibodies that target the standard p40 subunit of the cytokines interleukin-12 and interleukin-23 (IL-12/23p40), which are involved in the pathogenesis of Crohn's disease.

Objectives: The objectives of this review were to assess the efficacy and safety of anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease.

Search methods: We searched the following databases from inception to 12 September 2016: PubMed, MEDLINE, EMBASE, and the Cochrane Library (CENTRAL). References and conference abstracts were searched to identify additional studies.

Selection criteria: Randomized controlled trials (RCTs) trials in which monoclonal antibodies against IL-12/23p40 were compared to placebo or another active comparator in patients with active Crohn's disease were included. DATA COLLECTION AND ANALYSIS: Two authors independently screened studies for inclusion and extracted data. Methodological quality was assessed using the Cochrane risk of bias tool. The primary outcome was failure to induce clinical remission, defined as a Crohn's disease activity index (CDAI) of < 150 points. Secondary outcomes included failure to induce clinical improvement, adverse events, serious adverse events, and withdrawals due to adverse events. Clinical improvement was defined as decreases of > 70 or > 100 points in the CDAI from baseline. We calculated the risk ratio (RR) and 95% confidence intervals (95% CI) for each outcome. Data were analyzed on an intention-to-treat basis. The overall quality of the evidence supporting the outcomes was evaluated using the GRADE criteria.

Main results: Six RCTs (n = 2324 patients) met the inclusion criteria. A low risk of bias was assigned to all studies. The two briakinumab trials were not pooled due to differences in doses and time points for analysis. In both studies there was no statistically significant difference in remission rates. One study (n = 79) compared doses of 1 mg/kg and 3 mg/kg to placebo. In the briakinumab group 70% (44/63) of patients failed to enter clinical remission at 6 or 9 weeks compared to 81% (13/16) of placebo patients (RR 0.86, 95% CI 0.65 to 1.14). Subgroup analysis revealed no significant differences by dose. The other briakinumab study (n = 230) compared intravenous doses of 200 mg, 400 mg and 700 mg with placebo. Eighty-four per cent (154/184) of briakinumab patients failed to enter clinical remission at six weeks compared to 91% (42/46) of placebo patients (RR 0.92, 95% CI 0.83 to 1.03). Subgroup analysis revealed no significant differences by dose. GRADE analyses of the briakinumab studies rated the overall quality of the evidence for the outcome clinical remission as low. Based on the results of these two studies the manufacturers of briakinumab stopped production of this medication. The ustekinumab studies were pooled despite differences in intravenous doses (i.e. 1mg/kg, 3 mg/kg, 4.5 mg/kg, and 6 mg/kg), however the subcutaneous dose group was not included in the analysis, as it was unclear if subcutaneous was equivalent to intravenous dosing. There was a statistically significant difference in remission rates. At week six, 84% (764/914) of ustekinumab patients failed to enter remission compared to 90% (367/406) of placebo patients (RR 0.92, 95% CI 0.88 to 0.96; 3 studies; high-quality evidence). Subgroup analysis showed a statistically significant difference for the 6.0 mg/kg dose group (moderate-quality evidence). There were statistically significant differences in clinical improvement between ustekinumab and placebo-treated patients. In the ustekinumab group, 55% (502/914) of patients failed to improve clinically (i.e. 70-point decline in CDAI score), compared to 71% (287/406) of placebo patients (RR 0.78, 95% CI 0.71 to 0.85; 3 studies). Subgroup analysis revealed significant differences compared to placebo for the 1 mg/kg, 4.5 mg/kg and 6 mg/kg dosage subgroups. Similarly for a 100-point decline in CDAI, 64% (588/914) of patients in the ustekinumab group failed to improve clinically compared to 78% (318/406) of placebo patients (RR 0.82, 95% CI 0.77 to 0.88; 3 studies; high-quality evidence). Subgroup analysis showed a significant difference compared to placebo for the 4.5 mg/kg and 6.0 mg/kg (high-quality evidence) dose groups. There were no statistically significant differences in the incidence of adverse events, serious adverse events or withdrawal due to adverse events. Sixty-two per cent (860/1386) of ustekinumab patients developed at least one adverse event compared to 64% (407/637) of placebo patients (RR 0.97, 95% CI 0.90 to 1.04; 4 studies; high-quality evidence). Five per cent (75/1386) of ustekinumab patients had a serious adverse event compared to 6% (41/637) of placebo patients (RR 0.83, 95% CI 0.58 to 1.20; 4 studies; moderate-quality evidence). The most common adverse events in briakinumab patients were injection site reactions and infections. Infections were the most common adverse event in ustekinumab patients. Worsening of Crohn's disease and serious infections were the most common serious adverse events.

Authors' conclusions: High quality evidence suggests that ustekinumab is effective for induction of clinical remission and clinical improvement in patients with moderate to severe Crohn's disease. Moderate to high quality evidence suggests that the optimal dosage of ustekinumab is 6 mg/kg. Briakinumab and ustekinumab appear to be safe. Moderate quality evidence suggests no increased risk of serious adverse events. Future studies are required to determine the long-term efficacy and safety of ustekinumab in patients with moderate to severe Crohn's disease.

PubMed Disclaimer

Conflict of interest statement

John MacDonald: None known.

Tran Nguyen: None known

Reena Khanna has received honoraria from AbbVie, Jansen, Pfizer, Shire, and Takeda for consultancy. All of these activities are outside the submitted work.

Antje Timmer received grants (paid to institution) from Sanofi‐Aventis, Bayer, Takeda, Celgene, and Novartis for pharmacoepidemiological studies; and payment for lectures from The Falk Foundation, and MSD Sharp. All of these activities are outside the submitted work.

Figures

1
1

Study flow diagram.

2
2

Risk of bias summary: reviewers' judgements about each risk of bias item for each included study.

1.1
1.1. Analysis

Comparison 1 Briakinumab versus placebo, Outcome 1 Failure to induce clinical remission (7 & 9 weeks).

1.2
1.2. Analysis

Comparison 1 Briakinumab versus placebo, Outcome 2 Failure to Induce clinical remission (6 weeks).

1.3
1.3. Analysis

Comparison 1 Briakinumab versus placebo, Outcome 3 Failure to induce clinical response (>= 100 points; 7 & 9 weeks).

1.4
1.4. Analysis

Comparison 1 Briakinumab versus placebo, Outcome 4 Failure to induce clinical response (>= 100 points; 6 weeks).

1.5
1.5. Analysis

Comparison 1 Briakinumab versus placebo, Outcome 5 Adverse events.

1.6
1.6. Analysis

Comparison 1 Briakinumab versus placebo, Outcome 6 Serious adverse events.

1.7
1.7. Analysis

Comparison 1 Briakinumab versus placebo, Outcome 7 Withdrawals because of adverse events.

2.1
2.1. Analysis

Comparison 2 Ustekinumab versus placebo, Outcome 1 Failure to induce clinical remission (6 weeks).

2.2
2.2. Analysis

Comparison 2 Ustekinumab versus placebo, Outcome 2 Failure to induce clinical remission (6 weeks; sensitivity analysis).

2.3
2.3. Analysis

Comparison 2 Ustekinumab versus placebo, Outcome 3 Failure to induce clinical response (>= 70 points; 6 weeks).

2.4
2.4. Analysis

Comparison 2 Ustekinumab versus placebo, Outcome 4 Failure to induce clinical response (>= 70 points; 6 weeks; sensitivity analysis).

2.5
2.5. Analysis

Comparison 2 Ustekinumab versus placebo, Outcome 5 Failure to Induce clinical response (>=100 points; 6 weeks).

2.6
2.6. Analysis

Comparison 2 Ustekinumab versus placebo, Outcome 6 Failure to Induce clinical response (>=100 points; 6 weeks; sensitivity analysis).

2.7
2.7. Analysis

Comparison 2 Ustekinumab versus placebo, Outcome 7 Failure to induce clinical remission ‐ 90 mg, s.c. (6 weeks).

2.8
2.8. Analysis

Comparison 2 Ustekinumab versus placebo, Outcome 8 Failure to induce clinical response 90 mg s.c. (>= 70 points; 6 weeks).

2.9
2.9. Analysis

Comparison 2 Ustekinumab versus placebo, Outcome 9 Failure to induce clinical response 90 mg s.c. (>=100 points; 6 weeks).

2.10
2.10. Analysis

Comparison 2 Ustekinumab versus placebo, Outcome 10 Adverse events.

2.11
2.11. Analysis

Comparison 2 Ustekinumab versus placebo, Outcome 11 Serious adverse events.

2.12
2.12. Analysis

Comparison 2 Ustekinumab versus placebo, Outcome 12 Withdrawals because of adverse events.

Update of

Similar articles

Cited by

References

References to studies included in this review

Feagan 2016 UNITI‐1 {published data only}
    1. Adedokun OJ, Xu Z, Gasink C, Szapary P, Johanns J, Gao LL, et al. Pharmacokinetics and exposure‐response relationships of ustekinumab during IV induction and SC maintenance treatment of patients with Crohn's disease with ustekinumab: Results from the UNITI‐1, UNITI‐2, and IM‐UNITI studies. Gastroenterology 2016;150(4 Suppl 1):S408.
    1. Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR, et al. Ustekinumab as induction and maintenance therapy for Crohn's disease. New England Journal of Medicine 2016. - PubMed
    1. Li K, Hayden K, Wadman E, Bhagat S, Emrich S, Friedman J, et al. Molecular response to ustekinumab in moderate‐to‐severe Crohn's disease by serum protein analysis: Results from uniti‐1 induction, uniti‐2 induction, and imuniti maintenance studies. Gastroenterology 2016;150(4 Suppl 1):S377.
    1. Sandborn W, Gasink C, Blank M, Lang Y, Johanns J, Gao LL, et al. A multicenter, double‐blind, placebo‐controlled phase 3 study of ustekinumab, a human IL‐12/23P40 mAB, in moderate to severe Crohn's disease refractory to anti‐TFNalpha: UNITI‐1. Inflammatory Bowel Diseases 2016;22(Suppl 1):S1.
    1. Sandborn W, Gasink C, Jacobstein D, Gao L, Johanns J, Targan S, et al. Assessment of serum C‐reactive protein, fecal lactoferrin, and fecal calprotectin in patients with moderate‐severely active Crohns disease: Results from the IM UNITI maintenance study. Gastroenterology 2016;150(4 Suppl 1):S982.
Feagan 2016 UNITI‐2 {published data only}
    1. Feagan B, Gasink C, Lang Y, Friedman J, Johanns J, Gao L, et al. A multicenter, double‐blind, placebo‐controlled pH3 study of ustekinumab, a human monoclonal antibody to IL‐12/23p40, in patients with moderately‐severely active Crohn's disease who are not naive or not refractory to anti‐TNFa: UNITI‐2. Canadian Journal of Gastroenterology and Hepatology 2016;2016.
    1. Feagan B, Gasink C, Lang Y, Friedman JR, Johanns J, Gao LL, et al. A multicenter, double‐blind, placebo‐controlled pH3 study of ustekinumab, a human monoclonal antibody to IL‐12/23p40, in patients with moderately‐severely active Crohn's disease who are not naive or not refractory to anti‐TNFa: UNITI‐2. United European Gastroenterology Journal 2015;3(6):563‐4.
Mannon 2004 {published data only}
    1. Mannon P, Fuss I, Mayer L, Elson CO, Sandborn WJ, Dolin B, et al. Anti‐interleukin‐12 treats active Crohn's disease. Gastroenterology 2004;126(4 Suppl 2):A22‐3.
    1. Mannon PJ, Fuss IJ, Mayer L, Elson CO, Sandborn WJ, Present D, et al. Anti‐interleukin‐12 antibody for active Crohn's disease. New England Journal of Medicine 2004;351(20):2069‐79. - PubMed
Panaccione 2015 {published and unpublished data}
    1. Panaccione R, Sandborn W, Gordon G, Lee S, Safdi A, Sedghi S, et al. Briakinumab (anti‐interleukin 12/23p40, ABT874) for treatment of Crohn's disease. American Journal of Gastroenterology 2010;105(Supp 1):S457‐8.
    1. Panaccione R, Sandborn WJ, Gordon GL, Lee SD, Safdi A, Sedghi S, et al. Briakinumab for treatment of Crohn's disease: results of a randomized trial. Inflammatory Bowel Diseases 2015;21(6):1329‐40. - PMC - PubMed
Sandborn 2008 {published data only (unpublished sought but not used)}
    1. Sandborn W, Feagan B, Fedorak R, Scherl E, Fleisher M, Katz S, et al. A multicenter, randomized, phase 2A study of human monoclonal antibody to IL‐ 12/23P40 (CNTO 1275) in patients with moderately to severely active Crohn’s disease. Inflammatory Bowel Diseases 2008;14(Supp 1):S10.
    1. Sandborn WJ, Feagan BG, Fedorak R, Scherl E, Fleisher M, Katz S, et al. A multicenter, randomized, phase 2a study of human monoclonal antibody to IL‐12/23p40 (CNTO 1275) in patients with moderately to severely active Crohn's disease. Gastroenterology 2007;132(4 Suppl 1):A51.
    1. Sandborn WJ, Feagan BG, Fedorak RN, Scherl E, Fleisher MR, Katz S, et al. A randomized trial of ustekinumab, a human interleukin‐12/23 monoclonal antibody, in patients with moderate‐to‐severe Crohn's disease. Gastroenterology 2008;135(4):1130‐41. - PubMed
    1. Toedter GP, Blank M, Lang Y, Chen D, Sandborn WJ, Villiers WJ. Relationship of C‐reactive protein with clinical response after therapy with ustekinumab in Crohn's disease. American Journal of Gastroenterology 2009;104(11):2768‐73. - PubMed
Sandborn 2012 {published data only}
    1. Ding T, Telesco S, Monast C, Brodmerkel C, Yatsunenko T, Das A, et al. [The gut microbiome differentiates clinical phenotypes in moderate to severe Crohn's disease: Results from the certifi study]. Canadian Journal of Gastroenterology and Hepatology 2016;2016.
    1. Ding T, Telesco S, Monast CS, Brodmerkel C, Yatsunenko T, Das A, et al. [The gut microbiome differentiates clinical phenotypes in moderate to severe Crohn's disease: Results from the certifi study]. Gastroenterology 2015;148(4 Suppl 1):S713.
    1. Ding T, Telesco S, Monast CS, Brodmerkel C, Yatsunenko T, Das A, et al. [The gut microbiome differentiates clinical phenotypes in moderate to severe Crohn's disease: Results from the CERTIFI study]. United European Gastroenterology Journal 2015;3(5 Suppl 1):A133‐4.
    1. Feagan B, Gasink C, Gao L, Blank M, Johanns J, Guzzo C, et al. A multicenter, randomized, double‐blind, placebo‐controlled phase 2B study of ustekinumab, a human monoclonal antibody to IL‐12/23P40, in patients with moderately to severely active Crohn's disease: Results through week 36 from the CERTIFI trial. American Journal of Gastroenterology 2011;106(Supp 2s):S463.
    1. Feagan B, Gasink C, Gao LL, Blank M, Johanns J, Guzzo C, et al. Health related quality of life results through week 22 from the CERTIFI study, a multicenter, randomized, double‐blind, placebo‐controlled Phase2b study of ustekinumab in patients with moderately to severely active Crohn's disease. Journal of Crohn's and Colitis 2012;6(Supp 1):S129‐30.

References to studies excluded from this review

Fasanmade 2008 {unpublished data only}
    1. Fasanmade AA, Adedokun OJ, Johanns JR, Zhou H, Davis HM, Blank, M. Pharmacokinetics and exposure‐response relationship of ustekinumab, a human monoclonal antibody to interleukin 12/23 in patients with moderate‐to‐severe Crohn's disease. Gastroenterology 2008;134(4 Suppl 1):A‐490.
Sands 2010 {published data only}
    1. Sands BE, Jacobson EW, Sylwestrowicz T, Younes Z, Dryden G, Fedorak R, et al. Randomized, double‐blind, placebo‐controlled trial of the oral interleukin‐12/23 inhibitor apilimod mesylate for treatment of active Crohn's disease. Inflammatory Bowel Diseases 2010;16(7):1209‐18. - PubMed

References to ongoing studies

NCT01369329 {published data only}
    1. NCT01369329. A phase 3, randomized, double‐blind, placebo‐controlled, parallel‐group, multicenter study to evaluate the safety and efficacy of ustekinumab induction therapy in subjects with moderately to severely active Crohn's disease who have failed or are intolerant to TNF antagonist therapy (UNITI‐1). clinicaltrials.gov/ct2/show/NCT01369329 (accessed March 31, 2015).
NCT01369342 {published data only}
    1. NCT01369342. A phase 3, randomized, double‐blind, placebo‐controlled, parallel‐group, multicenter study to evaluate the safety and efficacy of ustekinumab induction therapy in subjects with moderately to severely active Crohn's disease (UNITI‐2). clinicaltrials.gov/ct2/show/NCT01369342 (accessed 31 March 2015).
NCT01369355 {published data only}
    1. NCT01369355. A phase 3, randomized, double‐blind, placebo‐controlled, parallel‐group, multicenter study to evaluate the safety and efficacy of ustekinumab maintenance therapy in subjects with moderately to severely active Crohn's disease. clinicaltrials.gov/ct2/show/NCT01369355 (accessed 31 March 2015).

Additional references

Akobeng 2003
    1. Akobeng AK, Zachos M. Tumor necrosis factor‐alpha antibody for induction of remission in Crohn's disease. Cochrane Database of Systematic Reviews 2003, Issue 4. [DOI: 10.1002/14651858.CD003574.pub2] - DOI - PMC - PubMed
Benson 2011
    1. Benson JM, Sachs CW, Treacy G, Zhou H, Pendley CE, Brodmerkel CM, et al. Therapeutic targeting of the IL‐12/23 pathways: generation and characterization of ustekinumab. Nature Biotechnology 2011;29(7):615‐24. - PubMed
Burmester 2013
    1. Burmester GR, Panaccione R, Gordon KB, McIlraith MJ, Lacerda AP. Adalimumab: long‐term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease. Annals of the Rheumatic Diseases 2013;72(4):517‐24. - PMC - PubMed
Chande 2013
    1. Chande N, Tsoulis DJ, MacDonald JK. Azathioprine or 6‐mercaptopurine for induction of remission in Crohn's disease. Cochrane Database of Systematic Reviews 2013, Issue 4. [DOI: 10.1002/14651858.CD000545.pub4] - DOI - PubMed
Cingoz 2011
    1. Cingoz, O. Ustekinumab. Monoclonal Antibodies 2011;1(3):216‐221.
Colombel 2004
    1. Colombel JF, Loftus EV Jr, Tremaine WJ, Egan LJ, Harmsen WS, Schleck CD, et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology 2004;126(1):19‐31. - PubMed
Colombel 2007
    1. Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007;132(1):52‐65. - PubMed
Colombel 2010
    1. Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. New England Journal of Medicine 2010;362(15):1383‐95. - PubMed
Danese 2011
    1. Danese S, Fiorino G, Reinisch W. Review article: Causative factors and the clinical management of patients with Crohn's disease who lose response to anti‐TNF‐α therapy. Alimentary Pharmacology and Therapeutics 2011;34(1):1‐10. - PubMed
Duvallet 2011
    1. Duvallet E, Semerano L, Assier E, Falgarone G, Boissier MC. Interleukin‐23: a key cytokine in inflammatory diseases. Annals of Medicine 2011;43(7):503‐11. - PubMed
Faubion 2001
    1. Faubion WA Jr, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of corticosteroid therapy for inflammatory bowel disease: a population‐based study. Gastroenterology 2001;121(2):255‐60. [PUBMED: 11487534] - PubMed
Ford 2011
    1. Ford AC, Bernstein CN, Khan KJ, Abreu MT, Marshall JK, Talley NJ, et al. Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta‐analysis. American Journal of Gastroenterology 2011;106(4):590‐9. - PubMed
Fuss 1999
    1. Fuss IJ, Marth T, Neurath MF, Pearlstein GR, Jain A, Strober W. Anti‐interleukin 12 treatment regulates apoptosis of Th1 T cells in experimental colitis in mice. Gastroenterology 1999;117(5):1078‐88. [PUBMED: 10535870] - PubMed
Gottlieb 2009
    1. Gottlieb A, Menter A, Mendelsohn A, Shen YK, Li S, Guzzo C, et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double‐blind, placebo‐controlled, crossover trial. Lancet 2009;373(9664):633‐40. [PUBMED: 19217154] - PubMed
Gottlieb 2014
    1. Gottlieb AB, Kalb RE, Langley RG, Krueger GG, Jong EM, Guenther L, et al. Safety observations in 12095 patients with psoriasis enrolled in an international registry (PSOLAR): experience with infliximab and other systemic and biologic therapies. Journal of Drugs in Dermatology 2014;13(12):1441‐8. - PubMed
Guyatt 2008
    1. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck‐Ytter Y, Alonso‐Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336(7650):924‐6. - PMC - PubMed
Hanauer 2002
    1. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359(9317):1541‐9. - PubMed
Hanauer 2006
    1. Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, et al. Human anti‐tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC‐I trial. Gastroenterology 2006;130(2):323‐33. - PubMed
HIggins 2011a
    1. Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Higgins 2011b
    1. Higgins JPT, Deeks JJ, Altman DG (editors). Chapter 16: Special topics in statistics. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Hudesman 2013
    1. Hudesman D, Lichtiger S, Sands B. Risk of extraintestinal solid cancer with anti‐TNF therapy in adults with inflammatory bowel disease: review of the literature. Inflammatory Bowel Diseases 2013;19(3):644‐649. - PubMed
Khanna 2013
    1. Khanna R, Feagan BG. Ustekinumab for the treatment of Crohn's disease. Immunotherapy 2013;5(8):803‐15. - PubMed
Lawson 2006
    1. Lawson MM, Thomas AG, Akobeng AK. Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis. Cochrane Database of Systematic Reviews 2006, Issue 3. [DOI: 10.1002/14651858.CD005112.pub2] - DOI - PubMed
Loke 2007
    1. Loke YK, Price D, Herxheimer A, Cochrane Adverse Effects Methods Group. Systematic reviews of adverse effects: framework for a structured approach. BMC Medical Research Methodology 2007;7:32. - PMC - PubMed
McDonald 2012
    1. McDonald JWD, Tsoulis DJ, MacDonald JK, Feagan BG. Methotrexate for induction of remission in refractory Crohn's disease. Cochrane Database of Systematic Reviews 2012, Issue 12. [DOI: 10.1002/14651858.CD003459.pub3] - DOI - PubMed
Modigliani 1990
    1. ModiglianiR, Mary JY, Simon JF, Cortot A, Soule JC, Gendre JP, et al. Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Thérapeutique des Affections Inflammatoires Digestives. Gastroenterology 1990;98(4):811‐8. - PubMed
Molodecky 2012
    1. Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012;142(1):46‐54.e42; quiz e30. [PUBMED: 22001864] - PubMed
Neurath 1995
    1. Neurath MF, Fuss I, Kelsall BL, Stuber E, Strober W. Antibodies to interleukin 12 abrogate established experimental colitis in mice. Journal of Experimental Medicine 1995;182(5):1281‐90. [PUBMED: 7595199] - PMC - PubMed
Niederreiter 2013
    1. Niederreiter L, Adolph TE, Kaser A. Anti‐IL‐12/23 in Crohn's disease: bench and bedside. Current Drug Targets 2013;14(12):1379‐84. - PubMed
Papp 2008
    1. Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N, et al. Efficacy and safety of ustekinumab, a human interleukin‐12/23 monoclonal antibody, in patients with psoriasis: 52‐week results from a randomised, double‐blind, placebo‐controlled trial (PHOENIX 2). Lancet 2008;371(9625):1675‐84. [PUBMED: 18486740] - PubMed
Papp 2013
    1. Papp KA, Griffiths CE, Gordon K, Lebwohl M, Szapary PO, Wasfi Y, et al. Long‐term safety of ustekinumab in patients with moderate‐to‐severe psoriasis: final results from 5 years of follow‐up.. British Journal of Dermatology 2013;168(4):844‐54. - PubMed
Peluso 2006
    1. Peluso I, Pallone F, Monteleone G. Interleukin‐12 and Th1 immune response in Crohn's disease: pathogenetic relevance and therapeutic implication. World Journal of Gastroenterology 2006;12(35):5606‐10. - PMC - PubMed
Raj 2010
    1. Raj LS, Hawthorne AB. Optimising use of thiopurines in inflammatory bowel disease. Frontline Gastroenterology 2010;1:44‐51. - PMC - PubMed
Reich 2011
    1. Reich K, Langley RG, Papp KA, Ortonne JP, Unnebrink K, Kaul M, et al. A 52‐week trial comparing briakinumab with methotrexate in patients with psoriasis. New England Journal of Medicine 2011;365(17):1586‐96. - PubMed
RevMan 5 [Computer program]
    1. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.0. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2008.
Rutgeerts 1994
    1. Rutgeerts P, Löfberg R, Malchow H, Lamers C, Olaison G, Jewell D, et al. A comparison of budesonide with prednisolone for active Crohn's disease. New England Journal of Medicine 1994;331(13):842‐5. - PubMed
Sandborn 2007
    1. Sandborn WJ, Feagan BG, Stoinov S, Honiball PJ, Rutgeerts P, Mason D, et al. Certolizumab pegol for the treatment of Crohn's disease. New England Journal of Medicine 2007;357(3):228‐38. - PubMed
Schreiber 2007
    1. Schreiber S, Khaliq‐Kareemi M, Lawrance IC, Thomsen OØ, Hanauer SB, McColm J, et al. Maintenance therapy with certolizumab pegol for Crohn's disease. New England Journal of Medicine 2007;357(3):239‐50. - PubMed
Schünemann 2011
    1. Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Singh 2011
    1. Singh JA, Wells GA, Christensen, Ghogomu ET, Maxwell L, MacDonald JK, et al. Adverse effects of biologics: a network meta‐analysis and Cochrane overview. Cochrane database of systematic reviews 2011;2:CD008794. - PMC - PubMed
Singh 2014
    1. Singh S, Garg SK, Pardi DS, Wang Z, Murad MH, Loftus EV Jr. Comparative efficacy of biologic therapy in biologic‐naive patients with Crohn disease: a systematic review and network meta‐analysis. Mayo Clinic Proceedings 2014;89(12):1621‐35. - PubMed
Solberg 2007
    1. Solberg IC, Vatn MH, Hoie O, Stray N, Sauar J, Jahnsen J, et al. Clinical course in Crohn's disease: results of a Norwegian population‐based ten‐year follow‐up study. Clinical Gastroenterology and Hepatology 2007;5(12):1430‐8. - PubMed
Summers 1979
    1. Summers RW, Switz DM, Sessions JT Jr, Becktel JM, Best WR, Kern F Jr, et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology 1979;77(4 Part 2):847‐69. - PubMed
Targan 1997
    1. Targan SR, Hanauer SB, Deventer SJ, Mayer L, Present DH, Braakman T, et al. A short‐term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.. New England Journal of Medicine 1997;337(15):1029‐35. - PubMed
Watanabe 2004
    1. Watanabe T, Kitani A, Murray PJ, Strober W. NOD2 is a negative regulator of Toll‐like receptor 2‐mediated T helper type 1 responses. Nature Immunology 2004;5(8):800‐8. - PubMed
Yang 2002
    1. Yang YX, Lichtenstein GR. Corticosteroids in Crohn's disease. American Journal of Gastroenterology 2002;97(4):803‐23. - PubMed

Publication types

MeSH terms

Substances